Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Argatroban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 4/20 | 0.99 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.99 |
| ▸ | F10 | P00742 | 2/20 | 0.99 |
| ▸ | LMNA | P02545 | 1/20 | 0.99 |
| ▸ | PLAT | P00750 | 1/20 | 0.99 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.99 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Argatroban SCHEMBL20787652 | 1.00 | F2 (0.99) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL135173 | 0.99 | F2 (1.00) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL22974994 | 0.99 | F2 (1.00) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL18895186 | 0.99 | F2 (1.00) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL4375 | 0.99 | F2 (1.00) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL29741503 | 0.99 | F2 (1.00) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL20567702 | 0.99 | F2 (1.00) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL15019460 | 0.99 | F2 (1.00) | F2PRSS1F10LMNAPLAT | |
| SCHEMBL24209448 | 0.94 | F2 (0.90) | F2PRSS1F10LMNAPLAT | |
| SCHEMBL29566356 | 0.90 | F2 (0.84) | F2PRSS1F10LMNAPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131014-A1 | SUPRAMOLECULAR AGENTS DESIGN & USES THEREOF | UNIV GENEVE (CH) | 2026-05-14 | — | — | US | disclosed |
| EP-4658228-A1 | ECO-BIOLOGICAL COSMETIC COMPOSITION SUITABLE FOR REDUCING THE SIGNS OF CUTANEOUS AGEING | Thorel, Jean-Noël (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-3927817-B1 | NEW RECOMBINANT DIAMINE OXIDASE AND ITS USE FOR THE TREATMENT OF DISEASES CHARACTERIZED BY EXCESS HISTAMINE | UNIV WIEN MED (AT) | 2025-08-20 | — | — | EP | disclosed |
| US-20250073210-A1 | Use of Ergothioneine for Enhancing Glutathione Level | NANJING NUTRABUILDING BIO TECH CO LTD (CN) | 2025-03-06 | — | — | US | disclosed |
| EP-4460300-A1 | USE OF ERGOTHIONEINE FOR ENHANCING GLUTATHIONE LEVEL | Nanjing Nutrabuilding Bio-Tech Co., Ltd. (CN) | 2024-11-13 | — | — | EP | disclosed |
| US-20240366496-A1 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE BIRCH EXTRACT AND AT LEAST ONE BEECH BUD EXTRACT | CREDO (FR) | 2024-11-07 | — | — | US | disclosed |
| WO-2024186730-A1 | COMPOSITIONS FOR ENHANCED METABOLIC OXIDATION OF FATTY ACIDS | GRADS INNOVATION (US) | 2024-09-12 | — | — | WO | disclosed |
| CN-118510508-A | Use of ergothioneine for increasing glutathione levels | 南京纽邦生物科技有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2024161085-A1 | ECO-BIOLOGICAL COSMETIC COMPOSITION SUITABLE FOR REDUCING THE SIGNS OF CUTANEOUS AGEING | NAOS INSTITUTE OF LIFE SCIENCE (FR) | 2024-08-08 | — | — | WO | disclosed |
| US-20240215579-A1 | USE OF ANTI-CLOTTING COMPOUNDS AS RODENTICIDES | GULBA DIETRICH (DE) | 2024-07-04 | — | — | US | disclosed |
| US-20230226070-A1 | TREATMENT OF THROMBOSIS AND ASSOCIATED DISORDERS WITH AN ANTI-PLATELET AGENT. | THE HEART RESEARCH INSTITUTE LTD (AU) | 2023-07-20 | — | — | US | disclosed |
| WO-2023131078-A1 | USE OF ERGOTHIONEINE FOR ENHANCING GLUTATHIONE LEVEL | NANJING NUTRABUILDING BIO-TECH CO., LTD. (CN) | 2023-07-13 | — | — | WO | disclosed |
| US-11678659-B2 | Use as rodenticides of compounds that inhibit blood coagulation | GULBA DIETRICH (DE) | 2023-06-20 | — | — | US | disclosed |
| WO-2023089288-A1 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION COMPRISING AT LEAST ONE EXTRACT OF CYLINDROTHECA FUSIFORMIS AND AT LEAST ONE EXTRACT OF DUNALIELLA SALINA, AND COSMETIC USES THEREOF | BLUE LAB (FR) | 2023-05-25 | — | — | WO | disclosed |
| EP-4149477-A1 | TREATMENT OF THROMBOSIS AND ASSOCIATED DISORDERS WITH AN ANTI-PLATELET AGENT | The Heart Research Institute Ltd (AU) | 2023-03-22 | — | — | EP | disclosed |
| US-11491141-B1 | Methods of treating glutathione deficiencies and deficiencies in glutathione synthetase activity | NANJING NUTRABUILDING BIO-TECH CO., LTD. (CN) | 2022-11-08 | — | — | US | disclosed |
| WO-2022214485-A1 | USE OF ANTI-CLOTTING COMPOUNDS AS RODENTICIDES | BIOROXX GMBH (DE) | 2022-10-13 | — | — | WO | disclosed |
| EP-4070658-A1 | USE OF ANTICOAGULANT ACTIVE COMPOUNDS AS RODENTICIDE | BIORoxx GmbH (DE) | 2022-10-12 | — | — | EP | disclosed |
| WO-2022208005-A1 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE BIRCH EXTRACT AND AT LEAST ONE BEECH BUD EXTRACT | CREDO (FR) | 2022-10-06 | — | — | WO | disclosed |
| US-20220145269-A1 | NEW RECOMBINANT DIAMINE OXIDASE AND ITS USE FOR THE TREATMENT OF DISEASES CHARACTERIZED BY EXCESS HISTAMINE | UNIVERSITÄT FÜR BODENKULTUR WIEN (AT) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11491141-B1 | Methods of treating glutathione deficiencies and deficiencies in glutathione synthetase activity | GSS, GGT1, GSTA2 | F2 3396/4885PRSS1 323/4885F10 4389/4885 |
| US-11678659-B2 | Use as rodenticides of compounds that inhibit blood coagulation | PLAT, F2R, PLAUR | F2 11/4885PRSS1 199/4885F10 53/4885 |
| US-20230226070-A1 | TREATMENT OF THROMBOSIS AND ASSOCIATED DISORDERS WITH AN ANTI-PLATELET AGENT. | PLAT, PLA2G7, PIK3R5 | F2 219/4885PRSS1 139/4885F10 286/4885 |
| US-20250073210-A1 | Use of Ergothioneine for Enhancing Glutathione Level | GSS, GPX1, GSTA1 | F2 3386/4885PRSS1 349/4885F10 4334/4885 |
| US-20240215579-A1 | USE OF ANTI-CLOTTING COMPOUNDS AS RODENTICIDES | PLG, F13B, F2 | F2 3/4885PRSS1 175/4885F10 30/4885 |
| US-20260131014-A1 | SUPRAMOLECULAR AGENTS DESIGN & USES THEREOF | ADAR, RBM39, ANTXR2 | F2 94/4885PRSS1 3359/4885F10 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.